Hydroxy vardenafil
CAS: 224785-98-2
Ref. 3D-FH24158
1mg | Ausgelaufen | ||
2mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen |
Produktinformation
- 2-[2-Ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one4-[[3-(1,4 -Dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-1-piperazineethanol
- Imidazo[5,1-f][1,2,4]triazin-4(1H)-one, 2-[2-ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-5-methyl-7-propyl-
- Hydroxyvardenafil
- 2-[2-Ethoxy-5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]phenyl]-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one
- 1-Piperazineethanol, 4-[[3-(1,4-dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-
Hydroxy vardenafil is a dietary supplement that belongs to the group of sildenafil analogs. It is structurally similar to sildenafil and inhibits phosphodiesterase type-5 (PDE-5) in human liver cells. The hydroxy group at position 3 of vardenafil is responsible for its stability and long half-life, which allows it to be administered as a single dose. Hydroxy vardenafil has been shown to have a matrix effect on the plasma concentration of sildenafil and other PDE-5 inhibitors. Hydroxy vardenafil was found to be more potent than sildenafil in inhibiting PDE-5 activity in human liver cells.